Bloomberg Law
July 23, 2020, 8:17 PM

Myokardia Gets FDA Breakthrough Designation For Mavacamten

Sonali Pathirana

MyoKardia, Inc. said that the FDA has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).

  • company is currently preparing an NDA for mavacamten, with plans to submit to the FDA in the 1Q 2021
  • Shares rose 1.8% in post-market trading

To view the source of this information click here

To contact the reporter on this story:
Sonali Pathirana in New York at

To contact the editor responsible for this story:
Stephen Foxwell at

© 2020 Bloomberg L.P. All rights reserved. Used with permission. ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.